Elsevier

Heart Rhythm

Volume 11, Issue 7, July 2014, Pages 1109-1116
Heart Rhythm

B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias

https://doi.org/10.1016/j.hrthm.2014.04.024Get rights and content

Background

The cost-effective use of implantable cardioverter-defibrillators (ICDs) for the prevention of sudden cardiac death requires identification of patients at risk for ventricular tachyarrhythmias, not just for total mortality.

Objective

To determine whether N-terminal pro-B-type natriuretic peptide (NT-proBNP) or B-type natriuretic peptide (BNP) are independent predictors of ventricular arrhythmias in patients receiving primary prevention ICDs.

Methods

One hundred sixty-one patients with NT-proBNP levels and 403 patients with BNP levels at the time of ICD implantation were retrospectively assessed for the occurrence of first appropriate ICD therapy and mortality.

Results

In multivariable Cox proportional hazards regression analysis, NT-proBNP or BNP levels in the upper 50th percentile were the strongest predictor of ICD therapy after adjustment for sex, age, left ventricular ejection fraction, New York Heart Association class, history of coronary artery disease, blood urea nitrogen, creatinine clearance, and history of atrial fibrillation (hazard ratio [HR] 5.75, P < .001 for NT-proBNP; HR 3.40, P = .01 for BNP). Patients were divided into quartiles on the basis of NT-proBNP or BNP levels. The adjusted HR for ICD therapy in the highest and second highest quartiles of NT-proBNP levels (HR 12.9, P < .001, and HR 4.6, P = .03, respectively) were higher than the adjusted HR for total mortality in these 2 quartiles (HR 3.4, P = .021 and HR 2.3, P = .13, respectively). Similarly, the adjusted HR for ICD therapy in the highest and second highest quartiles of BNP levels (HR 4.74, P = .01 and HR 2.17, P = .04, respectively) were higher than the adjusted HR for total mortality in these 2 quartiles (HR 3.05, P = .01 and HR 1.07, P = .3, respectively).

Conclusion

In this study, elevated baseline NT-proBNP and BNP levels are independently associated with the risk for ventricular tachyarrhythmias, which significantly exceeds the risk for total mortality, in multivariable analysis.

Introduction

Sudden cardiac death (SCD) accounts for approximately 50% of total cardiovascular mortality.1 Even with appropriate use of optimal medical therapy in patients with structural heart disease, the implantable cardioverter-defibrillator (ICD) remains the most effective therapy shown to reduce the rate of SCD in this population. Although practice guidelines have designated left ventricular ejection fraction (LVEF) as the most important factor to be used in determining patient candidacy for ICD implantation,2 consensus panels find LVEF neither sensitive nor specific for the prediction of SCD.3, 4 In addition to LVEF, most risk variables incorporated into the multivariate models identified in the Multicenter UnSustained Tachycardia Trial (MUSTT),5 Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II),6 and Sudden Cardiac Death-Heart Failure Trial (SCD-HeFT)7 did not identify patients specifically at high risk for SCD. Indeed, patients at highest mortality risk in the MADIT-II trial did not experience survival benefit from ICDs, probably because deaths due to ventricular tachyarrhythmias (ie, SCD) represented a relatively smaller proportion of mortality as overall risk increased.8 Identifying variables that might predict a higher relative risk for SCD would help identify patients most likely to benefit from ICDs and thus remains an important goal of clinical electrophysiology investigation.

B-type natriuretic peptide (BNP) is released by cardiomyocytes in response to myocardial stretch and increased preload.9 In patients with chronic heart failure, stable coronary artery disease (CAD), and acute coronary syndromes, BNP is known to predict mortality independent of LVEF.10 The possibility that BNP or N-terminal pro-B-type natriuretic peptide (NT-proBNP) might predict the occurrence of arrhythmia is a logical extension of the known link11 between clinical heart failure and ventricular arrhythmias (VA) and has been proposed alongside emerging data about the molecular basis of stretch-activated depolarizing cation channels in cardiomyocytes.12, 13 Consequently, BNP has recently been evaluated as a potential predictor of SCD and VA in patients with ICDs.14, 15, 16, 17, 18 However, whether elevated BNP levels predict SCD independent of CHF status or LVEF remains controversial with conflicting evidence.19, 20, 21 In addition, it is not yet clear whether the association of BNP with VA and SCD is solely due to its relation with patients having more advanced disease and therefore at risk for higher total mortality. We performed this retrospective study to assess the association between BNP and NT-proBNP levels and VA in relation to total mortality in patients who have had ICDs implanted at our institutions over the last 10 years.

Section snippets

Patient population and data collection

In this 2-center retrospective study, patients who had NT-proBNP levels available within 9 months of the date of ICD implantation or BNP levels available within 12 months of the date of ICD implantation were identified among a cohort of all patients who had undergone initial ICD implantation at Beth Israel Deaconess Medical Center or Tufts Medical Center between October 2003 and July 2012 for the primary prevention of SCD. Patients were included if they underwent ICD implantation for the

Study population

A total of 695 patients who underwent ICD implantation for the primary prevention of SCD were identified: 202 patients from Beth Israel Deaconess Medical Center with available NT-proBNP levels and 493 patients from Tufts Medical Center with available BNP levels. Of these patients, we excluded 73 of 695 patients (10.5%) owing to insufficient data regarding clinical variables and 57 of 695 patients (8.2%) owing to cardiogenic shock or a heart failure hospitalization between the date of biomarker

Discussion

In this study, baseline NT-proBNP and BNP were highly associated with appropriate ICD therapy. Furthermore, the risk for ICD therapy increased out of proportion to the risk for total mortality. Elevated NT-proBNP and BNP levels remained independent predictors of appropriate ICD therapies after adjustment for variables that themselves are associated with the risk for VA or heart failure status, such as LVEF and NYHA functional class. HRs for NT-proBNP and BNP levels in the highest quartiles were

Conclusion

We have found that BNP and its prohormone NT-proBNP served as independent markers of VT and VF resulting in ICD therapy more than total mortality in 2 populations of patients undergoing ICD implantation for the primary prevention of SCD. These observations suggest that the association of natriuretic peptides with SCD and VA are not merely due to more advanced cardiac disease and failure. The measurement of these peptides should be incorporated into future prospective studies of multivariable

Acknowledgment

We thank Ms Dorothy Williams for invaluable assistance throughout this work.

References (30)

  • K. Tigen et al.

    N-terminal pro brain natriuretic peptide to predict prognosis in dilated cardiomyopathy with sinus rhythm

    Heart Lung Circ

    (2007)
  • B.L. Wilkoff et al.

    Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study

    J Am Coll Cardiol

    (2008)
  • D. Lloyd-Jones et al.

    Heart disease and stroke statistics—2010 update

    Circulation

    (2010)
  • A.E. Epstein et al.

    ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

    Circulation

    (2008)
  • A.P.M. Gorgels et al.

    The Maastricht Circulatory Arrest Registry. Out-of-hospital cardiac arrest—the relevance of heart failure

    Eur Heart J

    (2003)
  • Cited by (68)

    • European Resuscitation Council Guidelines 2021: Adult advanced life support

      2021, Resuscitation
      Citation Excerpt :

      Changes in left ventricular geometry affect the likelihood of developing VT and VF. High blood levels of B‐type natriuretic peptide (BNP) and its N‐terminal fragment (NT‐proBNP) are associated with higher rates of appropriate implantable cardioverter defibrillator (ICD) placement and mortality.51,52 The only indicator that has been identified to be consistently associated with an increased risk of SCD in the setting of CHD and left ventricular (LV) dysfunction is LV ejection fraction (LVEF).48

    • N-terminal pro–B-type natriuretic peptide is a specific predictor of appropriate device therapies in patients with primary prevention implantable cardioverter-defibrillators

      2021, Heart Rhythm
      Citation Excerpt :

      Because cardiomyocytes release N-terminal pro–B-type natriuretic peptide (NT-proBNP) in response to stretch, measurement of this peptide may conceivably predict the risk of ventricular arrhythmia. Lending credence to this idea, several studies have found that elevated NT-proBNP levels correlate with a high risk of SCD or appropriate ICD therapies.11–16 In addition, a retrospective analysis suggested that NT-proBNP levels might be specifically linked to ventricular arrhythmia risk elevated out of proportion to total mortality risk.11

    View all citing articles on Scopus
    View full text